Use of rhubarb anthraquinone compound in preventing and treating respiratory syncytial virus infectious disease

Abstract

The invention relates to an application of anthraquinones compound in preventing diseases infected by respiratory syncytial virus. The median poison concentration TC50 of anthraquinones compound for cell Hep-2 is 209.7 mg / ml; the median effective concentration LC50 for respiratory syncytial virus is 96.7 mg / ml; the treating index is 2.3; the inhibiting rate to cytopathic RSV cell is over 50% when drug concentration is over 128 ug / ml; and the larger of drug concentration, the higher of inhibiting rate. The side effect of nthraquinones compound is smaller than that of ribavirin, the process is simple and it can be prepared into various dosage forms.

Description

(1) Technical field: [0001] The invention relates to the application of rhubarb anthraquinone compounds, in particular to the application of rhubarb anthraquinone compounds in preventing and treating respiratory syncytial virus infectious diseases. (two) background technology: [0002] Respiratory syncytial virus (RSV) belongs to the genus Pneumovirus of the family Paramyxoviridae, which is the same genus as parainfluenza pathogens. They are both single-negative-sense RNA viruses and can cause upper and lower respiratory diseases. They are acute lower respiratory tract diseases in infants and young children. Infection with a common pathogen, almost all children under the age of 2 have been infected with RSV [8] . In recent years, RSV infection has been found to be an important virus in the elderly and immunosuppressed adults [9] . There is still no specific and effective treatment for RSV infection. The antiviral drug ribavirin (also known as Ribavirin, Ribavirin) has be...

AI Technical Summary

Problems solved by technology

At present, there is no safe and effective vaccine against RSV infection, so the research on anti-RSV drugs has become a topic of international medical attention in recent years.

Images